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Introduction
Anemia, defined by low hemoglobin (Hgb) concentrations in the 
blood, affects one-third of the world’s population, approximately 2 
billion people, and is especially prevalent in young children, women 
of childbearing age, and the elderly (1). Symptoms of anemia range 
from weakness, fatigue, and dizziness in milder cases to life-threat-
ening cardiovascular collapse in more severe cases, and chronic 
anemia leads to permanent neurocognitive deficits in children (2, 3). 
The most common causes of anemia are nutritional deficiencies 
(e.g., iron deficiency), primary hematologic diseases (e.g., sickle 
cell disease, thalassemia, myelodysplastic syndromes), drugs (e.g., 
cancer chemotherapy), and other chronic conditions that indirectly 
cause anemia (e.g., chronic kidney disease, inflammatory/autoim-
mune disorders, HIV) (4–7). Even in developed nations, anemia 
remains a major public health issue, as an estimated 85 million 
people are at high risk for anemia and 5 million people are afflicted 
by anemia, respectively, in the US alone (8–11).
Currently, the gold standard for anemia diagnosis is a com-
plete blood count (CBC) using a hematology analyzer, which mea-
sures the Hgb levels of a venous blood sample. As CBCs require a 
venous blood draw from a trained phlebotomist and hematology 
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Therefore, the device is feasible as a 
home-based test for self-screening 
or self-monitoring of anemia. Each 
test requires a single 5 μl drop of cap-
illary blood obtained via finger stick 
and can be interpreted with the naked 
eye. A clinical assessment study was 
conducted using blood samples from 
patients with anemia of different 
degrees and etiologies comparing 
visual interpretation of our POC test 
results by untrained users with clinical 
CBC Hgb levels obtained simultane-
ously. In addition, we present results 
from an optional custom color analysis 
smartphone app that integrates with 
the POC anemia test for automated 
Hgb level measurements and poten-
tial data transmission.
Results
Our color-based POC anemia test dif-
ferentiates among different degrees 
of anemia with a visual readout from 
a quick, inexpensive, disposable, 
and stand-alone device that does 
not require any additional equip-
ment or electrical power (Figure 1 
and STARD flowchart; the STARD 
flowchart can be found in the supple-
ment; supplemental material available 
online with this article; doi:10.1172/
JCI76666DS1). The device consists of 
2 parts, a cap and a body, with a color 
scale sticker attached to the latter (Fig-
ure 1A). The cap encases a sample tube 
for blood collection, and, after a finger 
stick is performed (Figure 1B), blood 
is collected via capillary action as it 
comes into contact with the sample 
tube (Figure 1C). Capillary action enables automatic filling of the 
entire sample tube and draws up a 5-μl aliquot of blood. The cap 
is then placed into the body of the device, which is prefilled with 
the reagent solution, until passive flexural latches engage (Fig-
ure 1D). After mixing, the blood then comes into contact with the 
reagent solution, initiating a redox reaction (Figure 1E). Within 
60 seconds, the solution undergoes a stable color change, and the 
Hgb level can then be estimated with the color scale sticker or with 
the optional smartphone app for automated analysis (Figure 1F). 
As normal Hgb levels range between 11.0 g/dl and 14.5 g/dl for 
children and adults (2, 17), the color-based POC test has been spe-
cifically optimized to detect different levels of anemia of clinical 
relevance: green-blue results indicate Hgb levels <9 g/dl, repre-
senting severe anemia; yellow results indicate Hgb levels between 
10 and 11 g/dl, representing mild anemia; and orange-red results 
indicate Hgb levels over 12 g/dl, representing no presence of ane-
mia (healthy). Supplemental Video 1 depicts use of the POC ane-
analyzers require a skilled technician and electrical power to oper-
ate, these devices are currently housed in hospitals, clinics, and 
commercial laboratories, necessitating patients to travel outside 
of their home to be tested for anemia. With anemia’s widespread 
prevalence, an inexpensive, disposable, stand-alone point-of-care 
(POC) anemia diagnostic that is simple enough for untrained peo-
ple to use as a self-test will enable (a) patients with chronic ane-
mia to self-monitor their disease, improve their quality of life, and 
potentially improve clinical outcomes and (b) the general public 
to self-screen for anemia in a cost-effective manner. While sev-
eral POC anemia diagnostics are currently available, all are cur-
rently designed for use by healthcare professionals and none are 
designed for home use as a self-test (12–16).
To those ends, here we present a visual color-based POC 
anemia test. The assay is rapid (<60 s), simple to use, disposable, 
and inexpensive and is a stand-alone system that does not require 
electrical power, additional equipment, or significant training. 
Figure 1. The POC color-based anemia test. (A) The device is comprised of 2 parts, a cap and a body. A 5-μl 
sample tube for precise and accurate blood collection is embedded in the cap. The body contains prefilled 
reagent solution that changes color when in contact with blood. A color scale sticker on the body enables 
user interpretation of the degree of anemia, if any. (B–E) Steps for using the POC color-based anemia test. 
(B) Perform a finger stick. (C) Collect blood until sample tube (within the cap) is filled via capillary action.  
(D) Insert cap into body and lock in place. (E) Mix and wait for 60 seconds and interpret resultant solution 
color. (F) Ranging from blue to red, resultant solution colors correlate with different Hgb levels, as indicated.
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such as the CIE L*a*b space (24, 25). Color analysis revealed that 
our absorbance data were primarily dependent on the red-green 
axis of the CIE L*a*b space and independent of the other axes. As 
such, a standard curve was then created to relate Hgb levels with 
quantified color using a* values, the red-green axis CIE L*a*b coor-
dinates, which were converted from the absorbance data of the 
resultant colors of the POC anemia test (Figure 2B and ref. 23). 
For these experiments, blood obtained from healthy donors was 
diluted with native plasma to obtain samples with Hgb levels rang-
ing from 5.5 and 17.2 g/dl, and our POC anemia test was run on 
each sample in quadruplicate. As shown, a second-order polyno-
mial fit indicates a strong correlation between resultant POC test 
color and Hgb level (r = 0.997).
A clinical assessment comparing our POC anemia test with a 
standard hematology analyzer was performed using blood sam-
ples obtained from patients (n = 238; see Supplemental Table 1 
for a list of patient diagnoses) with varying degrees of anemia and 
etiologies thereof and consisted of absorbance data, visual inter-
pretation by untrained users, and a colorimetric smartphone app 
for automated analysis. As an objective measure of the accuracy of 
our assay, absorbance data (λ = 350 nm to 750 nm) were obtained 
on a well plate reader. In addition, digital images of the resultant 
POC solutions were obtained via a standard smartphone camera 
under ambient indoor lighting conditions. To assess for assay vari-
ability, each clinical sample was tested in quadruplicate using 4 
separate POC anemia tests. Supplemental Figure 2 depicts clinical 
patient results using our POC test (n = 238), as analyzed with a* 
value versus clinical hematology analyzer Hgb levels. The average 
of the standard deviations of the separate POC test results for each 
clinical sample was 1.009 in a* value, corresponding to 0.20 g/dl 
Hgb, establishing the inter-test variability of our POC anemia test.
Visual estimates of the POC anemia test results versus clinical 
hematology analyzer Hgb levels from patient samples (n = 238) is 
presented in Figure 3. This aspect of the clinical assessment spe-
cifically involved 12 untrained adult subjects, with no known diag-
nosis of color blindness, who interpreted visual data and assessed 
a survey of the images of POC anemia test results that were 
obtained for each clinical sample. This usage of images allows for 
the assessment of inter-user variability, as each subject will view 
mia test in real time on a healthy sample (Hgb level: 15.1 g/dl), a 
borderline anemic sample (Hgb level: 11.5 g/dl), and a severely 
anemic sample (Hgb level: 8.0 g/dl).
Mechanistically, the assay involves a modification of the reac-
tion among Hgb, hydrogen peroxide, and 3,3′,5,5′-tetramethylben-
zidine (TMB), in which Hgb catalyzes a redox reaction between 
TMB and hydrogen peroxide, leading to oxidized TMB products 
that can be detected colorimetrically (see Supplemental Figure 1 
and ref. 18). This reaction has been well characterized (18–21) and 
has been used commercially for spectrophotometric detection of 
Hgb in plasma, qualitative detection of blood in stool samples, and 
crime scene investigation and in portable single-wavelength pho-
tometers for POC anemia testing (22, 23). Our group has repur-
posed and modified this reaction to (a) yield differential product 
ratios that exhibit different colorimetric properties spanning the 
visual spectrum, correlating with clinically relevant Hgb levels 
in whole blood, and (b) improve reagent stability and shelf-life. 
These novel modifications allow for the translation of this assay 
into a POC, disposable, visual color-based test for screening and 
monitoring anemia that does not require any additional spectro-
photometric equipment or electrical power.
Standard spectrophotometry was used to quantitatively analyze 
colorimetric aspects of our assay. Absorbance curves (λ = 350 nm 
to 750 nm) were obtained for whole blood samples of different 
Hgb levels, ranging from 8.0 g/dl to 16.1 g/dl (Figure 2A). Upon 
completion of the redox reaction, blood samples with different 
Hgb levels yielded different resultant colors and, as expected, were 
associated with characteristic absorbance curves. Absorbance 
curves revealed different maxima for each resultant color: red-
colored results (normal Hgb levels) are characterized by maxima 
at 540 nm and 575 nm, indicating the presence of heme, whereas 
yellow-colored results (mild to moderate anemia) are character-
ized by a maximum at 450 nm and blue- and green-colored results 
(severe anemia) are characterized by a maximum at 630 nm, indi-
cating the presence of oxidized TMB. To enable direct quantita-
tive comparisons with blood Hgb levels, the absorbance spectra 
are converted into single values, which can be accomplished by 
measuring the absorbance ratios at selected wavelengths or by 
converting the spectra into coordinates of color space systems, 
Figure 2. Quantification of POC color-based anemia test results. (A) Spectrophotometric absorbance curves for resultant solution colors for blood sam-
ples with Hgb levels of 8.0 g/dl, 9.1 g/dl, 10.5 g/dl, 11.6 g/dl, and 16.1 g/dl (λ = 450–700 nm, 5-nm step size). Absorbance maxima for the heme peaks are 
at 540 nm and 575 nm, and the maximum for the TMB peak is at 630 nm. (B) Standard curve was created using a single blood sample diluted in native 
plasma to create Hgb levels ranging between 5.5 g/dl and 17.2 g/dl. The final a* value, the coordinate in the CIE L*a*b space representing the balance of 
red-green color in each resultant solution, is plotted against Hgb level, as measured with a standard hematology analyzer. R value is 0.997.
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As a potential home diagnostic test, we also tested the capabil-
ity of our POC anemia test for serial Hgb level monitoring. Figure 5 
depicts POC color-based results over 45 days for a healthy control 
male, a healthy control female, and a male with β-thalassemia major, 
a genetic disease that causes chronic anemia, who receives monthly 
red blood cell transfusions. Absorbance ratios (540 nm/630 nm) 
were used to estimate Hgb levels, which were in agreement with 
the subjects’ corresponding Hgb levels obtained via hematology 
analyzer obtained the same days as the POC anemia tests were 
performed (Figure 5). As shown, the Hgb levels of the control male 
do not show any significant deviation from baseline throughout the 
course of the study. In contrast, the Hgb levels of the female control 
indicate lower Hgb at days 15 and 41, which coincided with men-
struation. The Hgb levels of the thalassemic subject were low on 
days 3, 27, and 41, which coincided with the days just prior to red 
cell transfusion. Overall, the color-based POC test was able to accu-
rately track distinguishable Hgb level changes over time.
Discussion
This color-based POC anemia test offers rapid, simple, inexpensive, 
and disposable self-screening and self-monitoring for anemia at 
home, requiring only a finger stick drop of capillary blood. The key 
unique aspects are its (a) visual color-based readout, enabling its 
use as a stand-alone system that does not require electrical power or 
additional equipment (such as a single-wavelength photometer); (b) 
low cost (each device currently costs US $0.50 to manufacture and is 
disposable); (c) small size and portability; and (d) ease of use, which 
enables users and patients to test themselves at their convenience. 
We have also developed an optional colorimetric smartphone app, 
with which the user simply takes an image of the resultant color 
change of the POC anemia test and the app outputs an estimated 
Hgb level on the smartphone screen. While not a requirement, this 
app provides automated analysis, with the built-in color scale sticker 
for users who are color-blind or prefer to not use their own judgment 
in estimating Hgb levels.
A clinical assessment determined that the POC anemia test 
obtained similar results to those of hematology analyzers (r = 0.864 
and r = 0.856 for visual interpretation and smartphone app, 
respectively), and both POC test analysis methods yielded com-
parable sensitivity and specificity for detecting anemia (<11 g/dl) 
(sensitivity: 90.2% and 91.1%, specificity: 83.7% and 79.2%, 
respectively) and severe anemia (<7 g/dl) (sensitivity: 90.0% and 
100%, specificity: 94.6% and 93.9%, respectively). These values 
are similar to those of existing POC anemia diagnostic tests, which 
currently are not designed for, and are not practical for, home use 
or use as a self-test (12–17, 26, 27). These data also highlight the 
the same images, although separately and independently. Using 
those images, the survey subjects were then asked to estimate the 
Hgb levels for each clinical sample based on the set of images and 
corresponding Hgb levels of the standard curve POC anemia test 
samples (Figure 2B). Clinical Hgb levels obtained via a hematol-
ogy analyzer correlated highly with visually interpreted Hgb levels 
(r = 0.864) (Figure 3). The average of the standard deviation among 
the surveyors’ Hgb level estimates for each clinical sample was 
0.67 g/dl Hgb, establishing the inter-user variability of our POC 
anemia test. According to CBC results, 178 patient samples indi-
cated presence of anemia (<11 g/dl); of these, 10 samples indicated 
presence of severe anemia (<7 g/dl). When setting anemia detec-
tion cutoffs at 7 g/dl and at 11 g/dl, representing the detection of 
severe anemia and the detection of any degree of anemia, respec-
tively, visual estimates of our POC anemia test indicate sensitiv-
ity and specificity values of 90.0% and 94.6%, respectively, when 
detecting severe anemia (<7 g/dl) and 90.2% and 83.7% when 
detecting the presence of any degree of anemia (<11 g/dl) (Table 1).
To enable automated analysis without requiring visual inter-
pretation on the user’s part as well as to enable color-blind patients 
to use our test, we developed an optional Java-based smartphone 
app that captures an image of the resultant POC anemia test and 
outputs an estimated Hgb level, based on CIE L*a*b space calcula-
tions, on the screen (Figure 4A). Clinical Hgb levels obtained via a 
clinical hematology analyzer correlated highly with smartphone app 
Hgb levels (r = 0.856) (Figure 4B). In addition, when setting anemia 
detection cutoffs at 7 g/dl and at 11 g/dl, representing the detection 
of severe anemia and the detection of any degree of anemia, respec-
tively, smartphone app calculations of our POC anemia test indicate 
sensitivity and specificity values of 100.0% and 93.9%, respectively, 
when detecting severe anemia (<7 g/dl) and 91.1% and 79.2% when 
detecting the presence of any degree of anemia (<11 g/dl) (Table 2). 
Clinical adult and pediatric visual interpretation and smartphone 
app analysis data are presented separately in Supplemental Figure 3.
Figure 3. Clinical assessment of POC color-based anemia test results via 
visual interpretation. Visually interpreted Hgb level averages (n = 12 visual 
interpreters) are plotted against clinical Hgb levels obtained via a hematol-
ogy analyzer for all patient samples (n = 238), showing a strong correlation 
(r = 0.864). Additionally, 95% prediction limits for the individual values 
were calculated (dashed lines).
Table 1. Sensitivity and specificity via visual interpretation
Sensitivity Specificity
Severe anemia (<7 g/dl) 90.0% 94.6%
Mild anemia (<11 g/dl) 90.2% 83.7%
Sensitivity and specificity of POC estimated Hgb via visual interpretation 
were calculated for detecting severe anemia (<7 g/dl) and the presence of 
any anemia (<11 g/dl).
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anemia and seek medical attention when their 
Hgb levels decrease significantly from their base-
line (9–11, 28). Indeed, chronic hemolytic anemia 
patients could potentially use this system for early 
self-detection of worsening anemia, which could 
be sudden, rapid, and potentially life threatening, 
in the context of viral infections or onset of acute 
complications in the case of sickle cell disease 
Finally, as our POC anemia test requires a small 
amount of blood (5 μl) from a simple finger stick, 
this diagnostic would be especially useful to min-
imize blood loss due to laboratory testing in neo-
nates and children, especially if Hgb levels need 
to be checked repeatedly (26).
In addition, our current chemical formulation 
yields color results correlating to different levels 
of anemia, as defined by the World Health Orga-
nization, <7 g/dl for severe anemia and <11 g/dl 
for mild anemia (29). This chemical formulation 
can be altered in a finely tuned manner to “shift” 
the color scale to correspond to different ranges 
of Hgb levels (Supplemental Figure 4). As shown, 
the resultant solution colors of the current chem-
ical formulation accurately differentiate between 
Hgb levels of 5.5 g/dl and 17.2 g/dl. The left-
shifted curve depicts another formulation of the 
POC anemia test that can produce different color 
results corresponding to Hgb levels ranging from 
2.5 g/dl to 9.1 g/dl and would be especially useful 
for diagnosing patients with severe anemia in the 
global health and low-resource settings. In con-
trast, the right-shifted curve depicts another for-
mulation designed to detect and differentiate Hgb 
levels ranging from 13.6 g/dl to 25.4 g/dl, and, as 
such, this formulation can be used to accurately 
diagnose the mildest forms of anemia as well as 
differing degrees of polycythemia. Therefore, the 
exact formulation of the POC anemia test will be 
dictated by the disease type and clinical scenario.
While several devices are currently available for POC anemia 
testing, the vast majority of these systems remain in the clinical 
setting, due to high costs and required technical skill for use, in 
comparison with our POC test. For example, portable POC devices 
that measure Hgb levels exist, but they are not stand-alone, con-
sisting of an electrically powered analyzer and disposable car-
tridges, and also require technical training (13, 26). The majority 
of these analyzers cost between US $1,000 and $2,000, with each 
test itself costing US $1–2 thereafter. More recently, noninvasive 
co-oximeters offering continuous Hgb level measurements have 
been developed, but they cost between US $1,000 and $3,000 
and also require electrical power and technical training (17, 22). In 
an attempt to introduce a simple, low-cost alternative for low-re-
source settings, the World Health Organization developed the 
Haemoglobin Colour Scale to test for anemia using the color of 
one’s blood to differentiate between Hgb levels, such that ane-
mic samples reflected a paler red color as compared with that of 
normal samples (12–16). While initial results indicated acceptable 
clinical utility of the smartphone app. While optional, as the POC 
anemia test is functional as a stand-alone device, the smartphone 
app not only enables automated analysis, color-blind users to 
operate the system, and the possibility of remote data transmis-
sion, it also increases the sensitivity of the test. Our continued 
development of the smartphone app will therefore likely further 
increase sensitivity of the POC anemia test.
Even in developed nations, this POC anemia test would serve 
multiple demographics and patient populations. For example, 
because of its low cost and ease of use, this system could be a 
cost-effective and convenient anemia self-screening method for 
the general population, especially those at risk for anemia, includ-
ing pregnant women, young children, and the elderly. In addition, 
chronically anemic patients, such as cancer patients receiving 
chemotherapy, patients with renal failure, patients with chronic 
inflammatory/immunologic disorders, or patients with primary 
hematologic disorders (e.g., sickle cell anemia, thalassemia, aplas-
tic anemia), could use this POC anemia test to self-monitor their 
Figure 4. Clinical assessment of POC color-based anemia test results via optional smart-
phone app. (A) Pictures depict the Java-based smartphone app analyzing anemic and healthy 
samples. The smartphone app obtains an image of the resultant solution color for an anemic 
sample (8 g/dl) and for a healthy sample (13 g/dl) and outputs Hgb levels of 7.7 g/dl and  
13.3 g/dl for the anemic and healthy samples, respectively, on the screen. (B) Smartphone app 
Hgb levels are plotted against clinical Hgb levels obtained via a hematology analyzer for all 
patient samples (n = 238), showing a strong correlation (r = 0.856). Additionally, 95% predic-
tion limits for the individual values were calculated (dashed lines).
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accuracy, follow-up field studies revealed suboptimal sensitivity 
and specificity, likely due to the level of technical training required 
to accurately perform and interpret the test (12).
As with any biochemical assay, our modified TMB-mediated 
reaction could be confounded by potential interfering substances. 
For blood, in particular, potential interference from byproducts of 
red cell destruction, which occur in hemolytic anemias (e.g., sickle 
cell anemia, thalassemias) must be assessed. Within our clini-
cal results, we determined that reticulocyte count, a metric of the 
degree of hemolysis, did not correlate with POC Hgb level deviation 
from the clinical Hgb level obtained from hematology analyzers. In 
addition, to determine whether the presence of bilirubin adversely 
affected the results of our POC anemia test, we systematically 
added bilirubin to existing blood samples, conducted our assay, 
and measured our assay’s Hgb levels based on spectrophotometry 
absorbance data. As shown in Supplemental Figure 5A, bilirubin 
levels between 0 and 5 mg/dl have negligible effects on our POC 
anemia test, and significant effects only occur at nonphysiologic lev-
els above 10 mg/dl. In addition, we determined that the presence 
of lipids in blood samples did not affect test results and neither did 
varying blood pH within physiological levels (Supplemental Figure 
5, B and C). Elevated levels of myoglobin can be detected in the 
blood following trauma (30), but even the highest tested myoglo-
bin concentrations (25 μl/mg) did not affect the POC anemia test 
results (Supplemental Figure 5D). The required redox reaction is 
affected by temperature and light, so each device is stored at 24°C in 
the dark until just prior to use. In addition, the devices can be stored 
at between 0°C and 40°C and remain accurate when equilibrated 
to and tested at room temperature (20°C–28°C). The resultant col-
ors are stable for over 15 minutes after the reaction is complete, and 
shelf life studies on our POC test revealed that our premixed solu-
tions stored at 24°C in the dark remained accurate after 6 months.
In today’s healthcare landscape, containing costs while 
improving patient empowerment and quality of life is of extreme 
importance. As such, POC diagnostics are taking on larger and 
more important roles in patient care; interest in developing home-
based self-tests, as ubiquitous as urine pregnancy tests and dia-
betic glucometers, is only increasing. Anemia is one of the most 
commonly diagnosed medical conditions, and the color-based 
POC test presented here offers a simple, rapid, and inexpensive 
way to self-test for anemia with a single drop of blood from a sim-
ple finger stick. In addition, we also envision our POC anemia test 
will be especially useful in low-resource settings, in which hema-
tology analyzers are cost prohibitive; studies are ongoing. Finally, 
the small blood volumes required of this assay enable it to be an 
ideal POC anemia test for neonates and pediatric patients. Over-
all, our results demonstrate the feasibility of this POC anemia test 
to function as a self-screening and self-monitoring tool for any 
patient who has or is at risk for anemia.
Methods
Color-based POC anemia testing. Each color-based POC anemia device 
was prefilled with 500 μl of a modified TMB and reagent solution and 
was coupled with a 5-μl straight, sodium heparin–coated, capillary 
tube (Innovative Med Tech) for blood collection. Blood sample prep-
aration for standard calibration curves experiments (Figure 2) and 
stability testing involved obtaining blood from a healthy subject via 
venipuncture procedure into a heparinized container. Blood was then 
centrifuged at 150 g for 10 minutes to separate plasma from red blood 
cells. Different dilutions (ranging from 6.8 g/dl to 17 g/dl, as indicated) 
were prepared by mixing different ratios of native red blood cells and 
platelet poor plasma. Hgb levels were determined via an Advia 2120 
Hematology System. All device prototypes were fabricated in the 
Global Center for Medicine Innovation.
Obtaining and processing patient blood samples. All patients enrolled 
in our study obtained a CBC for their clinical care the same day, typically 
immediately before, blood was obtained for the color-based POC ane-
mia test. Patient samples were obtained, and CBCs, which include a Hgb 
level, were run on standard clinical grade hematology analyzers (Advia 
2120i, Siemens Inc. and Heska Hematrue, Heska). Patient blood samples 
for the color-based POC anemia test were collected via finger stick with 
a spring-loaded lancing device (One Touch Ultra Soft) and a disposable 
21-gauge lancet. As quadruplicate measurements using the color-based 
POC anemia test were conducted for each sample (n = 4), 100–200 μl 
capillary blood was collected from each patient subject. Once the assay 
reaction was complete, equal portions of the solution were transferred 
into 4 wells of a 96-well plate. Absorbance values across the visual spec-
trum (λ = 350 nm to 750 nm, 5-nm step size) were then recorded using a 
well plate spectrophotometer (SpectraMax M2/M2e).
Table 2. Sensitivity and specificity via smartphone app
Sensitivity Specificity
Severe anemia (<7 g/dl) 100% 93.9%
Mild anemia (<11 g/dl) 91.1% 79.2%
Sensitivity and specificity of POC estimated Hgb via smartphone app were 
calculated for detecting severe anemia (<7 g/dl) and the presence of any 
anemia (< 11 g/dl).
Figure 5. Serial Hgb level monitoring with the POC anemia test. Over 45 
days, blood samples were obtained serially from a healthy adult man, a 
healthy adult woman, and a man with β-thalassemia major and tested via 
CBCs using a standard hematology analyzer and POC anemia test. Days 11 
and 37 mark the first day of the female subject’s menstrual cycle, which is 
reflected with lower Hgb levels on days 15 and 41. The man with β-thalas-
semia major was transfused on days 7 and 30, indicating relatively higher 
Hgb levels than his anemic baseline.
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Overall, 238 clinical blood samples from pediatric and adult patients 
were collected, tested, and analyzed using our POC anemia test and 
were compared with the patients’ clinical CBC results. There were no 
adverse effects experienced by study subjects. In addition, one healthy 
adult male, one healthy adult female, and one male with β-thalassemia 
major were recruited for serial testing over 45 days (n = 1 data point per 
subject per day tested). For this serial study, each sample was tested using 
our POC anemia test and a hematology analyzer, either an Advia 2120 
Hematology System or a Heska Hematrue analyzer (shown to correlate 
with the Advia system, r = 0.998). The research technician was blinded 
to golden standard CBC results until testing was complete. Each sample 
was tested in quadruplicate (n = 4) using the POC anemia test.
Assay color quantification via a* value analysis. To enable head-to-
head comparison of the color-based POC anemia test with Hgb lev-
els obtained from a standard clinical hematology analyzer, the color 
changes the reagent undergoes must be quantified and distilled to a 
single number. One method commonly used in spectroscopy is to 
take the ratio of 2 absorbance intensity peaks, as shown in Figure 2A. 
Another method involves conversion of absorbance data into CIE 
L*a*b* space data (24). Absorbance data across the visual spectrum 
(λ = 350 nm to 750 nm, 5-nm step size) were obtained with a well plate 
spectrophotometer (SpectraMax M2/M2e) and imported into MAT-
LAB. The code analyzed color as a value of a* and correlated values to 
Hgb levels using the procedure described below.
Colors correspond to the CIE L*a*b* (CIELAB) color space. The 
CIELAB space is a tricoordinate color space, wherein the L*, a*, and b* 
coordinates correspond to the white-black, red-green, and yellow-blue 
balances of a given color, respectively (24, 25). The CIELAB color 
space was originally generated to allow for a perceptually uniform 
color space, hence changes in colors should accompany a change in 
quantified color value (24). To generate comparable color data in the 
CIELAB space, absorbance data spanning λ = 350 nm to 750 nm, 5-nm 
step size, was used to first calculate color values in the CIE 1931 XYZ 
space, using the equations listed below.
    (Equation 1)
    (Equation 2)
    (Equation 3)
    (Equation 4)
S(λ) is the relative spectral power distribution of a standard illu-
minant, in this case a D50 source. x̄(λ), ȳ(λ), and z̄(λ), supplied by 
the CIE, are the 1931 spectral tristimulus values. R(λ) is the spectral 
reflectance (or transmittance) of the object measured. The values of 
X, Y, and Z were then used to calculate values for L*, a*, and b* using 
the following equations:
    (Equation 5)
    (Equation 6)
    (Equation 7)
Xn, Yn, and Zn are the CIE tristimulus of the reference white point. 
A script to process these calculations was written in MATLAB. It was 
noted that the L* and b* values were largely independent of the Hgb 
levels. As such, a* values, which are dependent on the red-green color 
balance in each result, correlate to our color scale and, therefore, the 
Hgb level for each sample (Figure 2 and Supplemental Figure 2).
Assay color quantification via an optional smartphone app. Colo-
rimetric analysis was performed using custom software written in 
MATLAB. A calibration function relating Hgb concentrations to peak 
histogram values for each RGB channel was used to estimate the Hgb 
concentration for all sample images. The calibration function was cre-
ated using images of processed POC anemia devices containing blood 
samples with known Hgb levels (the same standard calibration results 
presented in Figure 2B). The center 25% of each calibration image was 
selected as the region of interest (ROI). RGB values in the ROI were 
converted to CIE L*a*b* color space using a D50 luminator white point. 
A histogram for each channel (L*, a*, and b*) in the ROI was calculated. 
Peaks of the channel histograms for each calibration image and corre-
sponding Hgb value were fit using planar regression with the following 
function: estimated Hgb level = w + x*(L*peak) + y*(a* peak) + z*(b* peak).
This MATLAB function was then converted into a Java-based app 
for performance on an Android-powered mobile phone. The smart-
phone app allows the user to take a digital photographic image of 
the resultant solution color and obtain an estimated digital Hgb level 
result based on the same function used in MATLAB. After image cap-
ture, the app saves the image and outputs an estimated Hgb level on 
screen (Figure 4A). Using this app, Hgb concentrations were estimated 
for clinical samples (Figure 4B).
Visual-based analysis. Using a standard smartphone (iPhone 4, iOS 
6) set to default lighting and focusing, images were obtained of all pro-
cessed POC anemia tests (the entire device, including the reagent solu-
tions after the reaction was completed) using patient blood samples. 
These images were then were placed in randomized order and compiled 
into surveys. A blinded study was then conducted in which 12 untrained 
adult subjects (6 women and 6 men with no known diagnosis of any 
form of color blindness) were asked to visually interpret and assign 
Hgb values of the images using a color scale, which was based on colors 
obtained from POC anemia tests of different but known Hgb levels.
Statistics. All statistical analyses were performed using SAS 9.3. A 
P value of less than 0.05 was considered significant. Pearson correla-
tions and general linear regression models and prediction limits were 
used to assess associations between Hgb level via hematology ana-
lyzer and absorbance ratio, a* value, visually interpreted Hgb level, 
and smartphone app Hgb level. Individual patients were identified 
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as either adult or pediatric and investigated for differences in their 
outcomes via analysis of covariance, controlling for the Hgb level via 
hematology analyzer covariate. In cases when the assumption of equal 
regression slopes was violated, linear regression models were run 
separately for adult and pediatric patients. Sensitivity and specificity 
results were calculated with both adult and pediatric patients together 
as well as by considering each patient type individually.
Study approval. Pediatric and adult patient blood samples were 
obtained in outpatient clinics of the Aflac Cancer and Blood Disorders 
Center of Children’s Healthcare of Atlanta and Emory’s Winship Can-
cer Center, respectively, by one consistent research technician using 
protocols approved by the IRBs of Emory University, Georgia Institute 
of Technology, and Children’s Healthcare of Atlanta. All samples were 
acquired after informed consent was obtained from patients or their 
parents/guardians. Each consented patient only provided one sample 
on the day of consent. 
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